A Look at the Life and Career of Dr. Lindsay Rosenwald
As a major player in the biotechnology sector, Dr. Lindsay Rosenwald is known as a pacesetter for the latest innovations in the healthcare and biotechnology industry. His portfolio of companies ranges from promising drug companies to research companies working on exciting new cancer drugs.
As a well known Wall Street venture capitalist, Dr. Lindsay Rosenwald possesses the pioneer spirit when searching for fresh, new investment opportunities. He has a strong reputation and almost two decades of experience as a venture capitalist investing in research and development, biotechnology and healthcare. Over the years, Dr. Rosenwald has made great contributions to the world of healthcare research and investing.
Over the course of his impressive 20 year career as an investor and hedge fund manager, Dr. Lindsay A. Rosenwald has been responsible for establishing and re-capitalizing numerous private and public companies within the sectors of biotechnology and life sciences. He has built many profitable, productive relationships over the years with these companies and their founders.
As one of the directors of the Republican Jewish Coalition, Dr. Lindsay Rosenwald also serves as president of Paramount Group Inc., a real estate investment and management firm. He considers one of his greatest accomplishments to be the founding of OpusPoint Partners, LLC located in New York. This relatively new company is committed to identifying and investing in various breakthroughs in healthcare and life science.
Dr. Rosenwald recently negotiated the sale of Cougar Biotechnology Inc. to Johnson & Johnson for nearly $1 billion dollars. Cougar Biotechnology is a development stage biopharmaceutical company that focuses on oncology. The company is currently conducting Phase III trials for a first-in-class compound for late-stage prostate cancer. The drug is called abiraterone acetate.
After only a few years in business, OpusPoint Partners LLC has already made great strides both in the world of investing and medicine. Dr. Lindsay Rosenwald believes that OpusPoint will continue to seek investment opportunities in cutting edge R&D and healthcare companies, searching for start-up businesses and publicly traded companies that will improve the quality of life.
Dr. Rosenwald and the team at OpusPoint Partners utilize their strengths and many years of experience to lead the way in the world of biotechnology and investing. Known as a visionary in these fields, Dr. Rosenwald was the first to invest in a new drug for obesity released in the U.S. market. He also participated in investing in the very first public gene therapy company, and often sees potential for medical breakthroughs that others might miss.
Dr. Lindsay Rosenwald is a graduate of Penn State University with a degree in finance. He received his MD from the Temple University School of Medicine completing his internship at Abington Medical Hospital.
OpusPoint Partners: Investing in Biotechnology’s Future
Advancements in the areas of life science and biotechnology are what OpusPoint Partners are all about. The company encourages original development of biotechnology ideas and supports those businesses that encompass a pioneering spirit. OpusPoint Partners consistently utilizes its knowledge of both the financial and healthcare world to make a difference in human health.
OpusPoint Partners first came together in 2009; the company is the product of Michael Weiss and Lindsay Rosenwald, M.D. This is the first combined venture for Rosenwald and Weiss, though individually they have been garnered much success in the life science and biotech industries. Both men bring over 20 years experience to the company; this includes founding and financing numerous biotechnology companies of their own over the years.
For Lindsay Rosenwald, one of his most recent individually successful ventures outside of OpusPoint Partners was his formation of Cougar Biotechnology Inc. This biotech company is located in Southern California and primarily researches and develops drugs to help combat cancer. Cougar Biotech has had some success with a drug for prostate cancer and has obtained the interest of researchers and investors alike. In 2009 Johnson & Johnson took notice and purchased the company for roughly one billion dollars.
OpusPoint Partners holds steadfast to expecting its associated biotech companies to abide by Rosenwald’s and Weiss’ strong principles of ethics in research and drug trials. OpusPoint Partners specifically looks for those biotech companies who have innovative ideas and the beginning foundation of sound business standards. Maintaining a business standard that crosses the board ensures the investors that their financial support is indeed secure. This investor confidence in turn aids in the development of the emergent biotech firms operating under the guidance of OpusPoint Partners and subsequently leads to necessary breakthroughs in the healthcare industry.
Lindsay Rosenwald is considered as a mentor of sorts to those biotechnology firms that OpusPoint Partners invests in; he brings his extensive expertise into play when he assists these companies in reaching their business goals. Because he has spent over 20 years in the same industry both creating and managing in excess of 50 biotech firms during this time, Rosenwald has much to offer these budding companies in an advisory context. Even though gaining appropriate financial backing is a key aspect for any emerging company, finding a mentor who can guide you to your end goal unimpeded is just as essential.
With Lindsay Rosenwald taking the lead at OpusPoint Partners, both individual and corporate investors can breathe a sigh of relief knowing that their investments are being managed properly and that transparency in the company’s dealings are being maintained. Rosenwald’s academic knowledge and professional experience in both the healthcare and financial sectors has proven to be an asset for OpusPoint Partners and its investors. He has shown that he understands what is required for a biotech firm to succeed and lay new groundwork in the medical field and because of this know-how the company has certainly shown their investors that minimal risk and optimal growth is attainable with OpusPoint Partners.
Lindsay Rosenwald brings a lot to the OpusPoint Partners table; he has spent a total of 17 years working in both finance on Wall Street and in developing biotechnology companies. Rosenwald’s academic pursuits include receiving a Bachelor of Science in Finance from Pennsylvania State University and a Doctor of Medicine from Temple University School of Medicine.
Rosenwald’s background in finance has proven quite useful in his career. From 1994 – 2007 he managed the Aries Fund, during 2000 alone he oversaw in excess of one billion in investments toward healthcare in this fund. He also managed the investments of the Orion Fund (2002 to 2006) whose funds are dedicated exclusively to biotechnology.
OpusPoint Partners along with Lindsay Rosenwald have their goals set on finding the brightest and most progressive biotechnology companies to invest in. It is these truly unique companies that will diligently and ethically work to create new technologies and drugs that will change the face of the healthcare industry as we know it.
OpusPoint Partners is a company that stands out for all of the right reasons. The co-founders Rosenwald and Weiss have over a short two year time span built up a well respected company that abides attentively to their inner moral compass. They do no encourage cutting corners or tampering with research or clinic trials, they do however promote the idea of upholding integrity in all aspects of the business world.
Making a change in the healthcare industry is no easy task, Lindsay Rosenwald along with OpusPoint Partners activity recognize this challenge. But, he doesn’t let this hinder him from staying the course and continuing to push down barriers in the life science and biotechnology fields. OpusPoint Partners and its associates continue to keep their aspirations on the ultimate prize, eradication of disease.
Because of the companies tenacity in biotechnology it is obvious to those operating in the both the financial and healthcare sectors that OpusPoint Partners is an investing do and not an investing don’t. Lindsay Rosenwald prides the OpusPoint Partners success on the fact that investors are privy to the financial dealings of the company every step of the way and the emergent biotech firms that are backed by investors are selected for their ingenuity, growth potential, and ethical principles.
Lindsay Rosenwald is constantly pursuing new investment leads in order to continue the expansion of OpusPoint Partners and to get closer to making significant advances in healthcare. When he is not focusing on his professional pursuits, Rosenwald takes part on the Board of Directors of the Republican Jewish Coalition.
OpusPoint Partners: Breaking Down Barriers in Life Science and Healthcare
Life science and healthcare is emerging into a new phase of innovative development. This development will see a world of better quality medicine and healthcare. OpusPoint Partners strive to be vanguards of this revolutionary shift with real and solid investments into cutting-edge methods. Their vision is to see humanity with greater access to improved healthcare.
With more than 40 years of experience between the two of them, Michael S. Weiss and Dr. Lindsay Rosenwald established OpusPoint Partners in 2009. The company is one of several biotechnology companies the two men have created together, expressing real passion for the field. They have created very solid careers in biotech investment and life science.
Another company started by Dr. Lindsay Rosenwald is Cougar Biotechnology Inc., located in Los Angeles. This company is largely concentrated on conducting experimental research for cancer drugs and has attracted attention from investors and researchers alike. One drug promises good potential for the treatment of prostate cancer in its late states. On July 10, 2009, Johnson & Johnson gained Cougar Biotech Labs for about one billion dollars.
Lindsay Rosenwald and OpusPoint Partners are keenly focused on building alliances with the biotechnology and investment communities. Key to strong relationships is the practice of integrity – part and parcel of an organization’s culture and good business practice. The associations built between companies and industry leaders can benefit from the practice of integrity which ensures honest investment and open and direct disclosures.
OpusPoint Partners and Lindsay Rosenwald are teaming up with researchers, investors and corporations to form a partnership of mutual support and to seek out the same interests in disease treatment that is groundbreaking. Dr. Lindsay Rosenwald and OpusPoint Partners will look for and invest in the most hopeful research companies on the verge of making big medical discoveries.
Dr. Lindsay Rosenwald and OpusPoint Partners plan to change the nature of biotech investing. They are insisting that biotech facilities adhere to high standards of morality and ethical business practices. They are showing, by example, that with these high standards, companies can achieve fruitful rewards without ignoring their responsibilities to good quality.
And Dr. Rosenwald is not a stranger to these practices. He was a biotechnology entrepreneur for over 17 years on Wall Street. He has also been an important player in the founding and recapitalization of several life science and biotech companies. He holds two degrees, one a B.S. in Finance from Pennsylvania State University and the other an M.D. from Temple University School of Medicine.
He has plenty of experience in large-scale financial investing. From 1994 to 2007, he managed The Aries Funds and from 2002 to 2006 he managed the Orion Fund. The Aries Funds invested over $1 billion dollars in healthcare; the Orion Fund contributed funds totally to private biotechnology investments, particularly PIPEs.
OpusPoint Partners’ is founded upon the aim of creating meaningful partnerships in the world of life science and healthcare. These partnerships reflect a mutual dedication to honesty and integrity. In today’s market, this kind of conglomeration may be a rarity, as business leaders may all too often neglect ethics in their goals of obtaining positive clinical trials and higher profit.
But OpusPoint Partners plans to provide an altogether different example. It has already shown its commitment to business integrity in the treatment of its shareholders (particularly to investors and employees). It has also shown its steady stance in applying ethical integrity to the process of drug testing, manufacture and investigation.
Guided by two very competent and successful leaders, OpusPoint Partners undoubtedly has a brilliant future. The shared experience, knowledge and expertise between Michael Weiss and Dr. Lindsay Rosenwald make the two leaders more than apt in guiding the company towards revolutionary change in healthcare and medicine.
It will not be easy, though, to alter traditional attitudes to medicine and healthcare. The collective effort will require time and money well-spent and a great deal of dedication and commitment to firm ethical boundaries.
Dr. Rosenwald, though, knows this is possible. OpusPoint Partners, in a small amount of time, has made important accomplishments. It has managed to help finance more than 20 companies in less than two years. It is clear that using the best practices can certainly produce attractive and ideal results in financing and drug research.
Dr. Lindsay Rosenwald serves the Republican Jewish Coalition as one of its board directors. He also maintains strong associations with leaders in the biotechnology financing industry. OpusPoint Partners looks forward to a progressive future under his leadership guidance.
LindsayRosenwald One Step Ahead In Investmet For LifeScience & HealthCare
OpusPoint Partners:
Investing in the Future ofHealthcare and Life Sciences
At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.
A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.
Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar's oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.
Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology. By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.
For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals. Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.
At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses. Sometimes it requires investing in publicly-traded companies.
Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.
For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.
An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.
The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.
The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.
But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money. It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.
Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone. This achievement is marked by a continuing commitment to the financial world and the world of drug research.
Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.
Lindsay Rosenwal Investing in Future ofLife Sciences and Healthcare
OpusPoint Partners is an innovative new company with a unique vision for the future of the life science and healthcare industry. That vision includes some cutting edge technologies but also some forward thinking business philosophies.
As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.
With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.
Advancements in the Future of Healthcare
Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.
One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.
Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.
Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.
Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.
With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.
The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.
Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.
One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.
Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?
At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.
A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.
Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.
Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.
Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.